{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:48:07Z","timestamp":1762530487926,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.adro.2022.101090","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T03:26:36Z","timestamp":1664767596000},"page":"101090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-5750","authenticated-orcid":false,"given":"Jonathan A.","family":"Baron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fantine","family":"Giap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond B. Mailhot","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"LaRiviere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Maity","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ima","family":"Paydar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2022.101090_bib0001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2014-05-575092","article-title":"Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: Do they require a unique therapeutic approach?","volume":"125","author":"Dunleavy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.adro.2022.101090_bib0002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11899-014-0219-0","article-title":"Primary mediastinal large B-cell lymphoma","volume":"9","author":"Dabrowska-Iwanicka","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.adro.2022.101090_bib0003","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2015.120","article-title":"PET\/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy","volume":"30","author":"Vassilakopoulos","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.adro.2022.101090_bib0004","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study","volume":"22","author":"Rieger","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0005","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","article-title":"Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: Impact of a PET-adapted approach","volume":"136","author":"Hayden","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.adro.2022.101090_bib0006","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428194.2018.1519812","article-title":"R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma","volume":"60","author":"Messmer","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.adro.2022.101090_bib0007","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3109\/10428194.2012.746684","article-title":"Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy","volume":"54","author":"Xu","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.adro.2022.101090_bib0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijrobp.2021.03.035","article-title":"Primary mediastinal B cell lymphoma in the positron-emission tomography era executive summary of the American Radium Society appropriate use criteria","volume":"111","author":"Hoppe","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101090_bib0009","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.adro.2022.101090_bib0010","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2022.101090_bib0011","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: A paradigm shift in clinical decision making","volume":"103","author":"Melani","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.adro.2022.101090_bib0012","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0013","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijrobp.2020.08.055","article-title":"Risk of pneumonitis and outcomes after mediastinal proton therapy for relapsed\/refractory lymphoma: A PTCOG and PCG collaboration","volume":"109","author":"Tseng","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101090_bib0014","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijrobp.2010.05.007","article-title":"Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma","volume":"81","author":"Li","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101090_bib0015","first-page":"15","article-title":"The evolution of proton beam therapy: Current and future status","volume":"8","author":"Tian","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0016","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijrobp.2011.06.1959","article-title":"Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: Preliminary dosimetric outcomes from a phase II study","volume":"83","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101090_bib0017","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0018","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13014-019-1432-8","article-title":"Comparative photon and proton dosimetry for patients with mediastinal lymphoma in the era of Monte Carlo treatment planning and variable relative biological effectiveness","volume":"14","author":"Tseng","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0019","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2022.101090_bib0021","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2019.238675","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.adro.2022.101090_bib0022","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2017.04.001","article-title":"Pulmonary toxicity following proton therapy for thoracic lymphoma","volume":"99","author":"Nanda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101090_bib0023","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ijrobp.2008.12.048","article-title":"Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: Conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy","volume":"75","author":"Chera","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101090_bib0024","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00066-019-01460-7","article-title":"Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: Clinical outcome and dosimetric comparison","volume":"195","author":"K\u00f6nig","year":"2019","journal-title":"Strahlentherapie Onkol"},{"key":"10.1016\/j.adro.2022.101090_bib0025","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.3109\/10428194.2015.1014364","article-title":"Proton therapy in the management of non-Hodgkin lymphoma","volume":"56","author":"Sachsman","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.adro.2022.101090_bib0026","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/j.ijrobp.2011.01.061","article-title":"Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin's lymphoma in female pediatric patients","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101090_bib0027","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: The International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.adro.2022.101090_bib0028","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1088\/0031-9155\/50\/3\/011","article-title":"Experimental characterization and physical modelling of the dose distribution of scanned proton pencil beams","volume":"50","author":"Pedroni","year":"2005","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.adro.2022.101090_bib0029","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1088\/0031-9155\/58\/12\/4137","article-title":"Interplay effects in proton scanning for lung: A 4D Monte Carlo study assessing the impact of tumor and beam delivery parameters","volume":"58","author":"Dowdell","year":"2013","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.adro.2022.101090_bib0030","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1080\/0284186X.2016.1191665","article-title":"Proton pencil beam scanning for mediastinal lymphoma: Treatment planning and robustness assessment","volume":"55","author":"Zeng","year":"2016","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.adro.2022.101090_bib0031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2017.05.014","article-title":"Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG thoracic and lymphoma subcommittee","volume":"99","author":"Chang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101090_bib0032","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.semradonc.2003.10.009","article-title":"Deep inspiration breath hold and respiratory gating strategies for reducing organ motion in radiation treatment","volume":"14","author":"Mageras","year":"2004","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0033","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0360-3016(00)00747-1","article-title":"Technical aspects of the deep inspiration breath-hold technique in the treatment of thoracic cancer","volume":"48","author":"Mah","year":"2000","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0034","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ijrobp.2015.11.049","article-title":"Deep inspiration breath hold-based radiation therapy: A clinical review","volume":"94","author":"Boda-Heggemann","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101090_bib0035","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.adro.2020.08.004","article-title":"Effect of deep inspiration breath hold on normal tissue sparing with intensity modulated radiation therapy versus proton therapy for mediastinal lymphoma","volume":"5","author":"Moreno","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0036","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/0284186X.2018.1512153","article-title":"Comparative treatment planning study for mediastinal Hodgkin's lymphoma: Impact on normal tissue dose using deep inspiration breath hold proton and photon therapy","volume":"58","author":"Edvardsson","year":"2019","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.adro.2022.101090_bib0037","doi-asserted-by":"crossref","first-page":"492","DOI":"10.14338\/IJPT-17-00012","article-title":"Comparing breath hold and free breathing during intensity-modulated radiation therapy and proton therapy in patients with mediastinal hodgkin lymphoma","volume":"3","author":"Hoppe","year":"2017","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.adro.2022.101090_bib0038","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0039","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3389\/fonc.2020.00989","article-title":"Secondary malignancy risk following proton vs. x-ray treatment of mediastinal malignant lymphoma: A comparative modeling study of thoracic organ-specific cancer risk","volume":"10","author":"K\u00f6nig","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fonc.2015.00261","article-title":"Secondary malignancy risk following proton radiation therapy","volume":"5","author":"Eaton","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2022.101090_bib0041","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/cncr.32938","article-title":"Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy","volume":"126","author":"Xiang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2022.101090_bib0042","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.15731","article-title":"The management of primary mediastinal B-cell lymphoma: A British Society for Haematology Good Practice paper","volume":"185","author":"Cwynarski","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.adro.2022.101090_bib0043","doi-asserted-by":"crossref","first-page":"196","DOI":"10.6004\/jnccn.2016.0023","article-title":"Diffuse large B-cell lymphoma version 1.2016","volume":"14","author":"Zelenetz","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.adro.2022.101090_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14338\/IJPT-20-00010.1","article-title":"Reducing heart dose with protons and cardiac substructure sparing for mediastinal lymphoma treatment","volume":"7","author":"Taparra","year":"2020","journal-title":"Int J Part Ther"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422001968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422001968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:42:34Z","timestamp":1762530154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109422001968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2452109422001968"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2022.101090","relation":{},"ISSN":["2452-1094"],"issn-type":[{"type":"print","value":"2452-1094"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2022.101090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101090"}}